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Abstract
Background: Artemisinin-based combination therapy (ACT) is the recommended first-line therapy for
uncomplicated Plasmodium falciparum malaria worldwide but decreased artemisinin susceptibility, phenotypically
characterized as slow parasite clearance time (PCT), has now been reported in Southeast Asia. This makes it all too
important to measure the dynamics of parasite clearance in African patients treated with ACT over time, to
understand trends and detect changes early enough to intervene
Methods: Individual patient data from 27 clinical trials of artesunate-amodiaquine (ASAQ) vs comparators
conducted between 1999 and 2009 were analysed for parasite clearance on modified intent-to-treat (ITT) basis.
Results: Overall 15,017 patients treated for uncomplicated P. falciparum malaria at 44 sites in 20 sub-Saharan African
countries were included in the analysis; 51% (n=7,660) vs 49% (n=7,357) were treated with ASAQ and comparator
treatments, respectively. Seventy-seven per cent (77%) were children under six years of age. The proportion of the
patients treated with ASAQ with persistent parasitaemia on Day 2 was 8.6%, and 1.5% on Day 3. Risk factor for not
clearing parasites on Day 2 and Day 3 calculated by multivariate logistic regression with random effect on site and
controlling for treatment were: high parasitaemia before treatment was (adjusted risk ratios (AOR) 2.12, 95% CI
1.91-2.35, AOR 2.43, 95% CI 1.98-3.00, respectively); non-ACT treatment (p=0.001, for all comparisons). Anaemia
(p=0.001) was an additional factor for Day 2 and young age (p=0.005) for Day 3.
In patients treated with ASAQ in studies who had complete parasitaemia data every 24 hours up to Day 3 and
additionally Day 7, the parasite reduction ratio was 93.9% by Day 1 and 99.9% by Day 2. Using the median
parasitaemia before treatment (p0=27,125 μL) and a fitted model, the predicted PCT (pPCT = 3.614*ln (p0) – 6.135,
r² = 0.94) in ASAQ recipients was 31 hours.
Conclusion: Within the period covered by these studies, rapid Plasmodium falciparum clearance continues to be
achieved in Sub-Saharan African patients treated with ACT, and in particular with ASAQ. The prediction formula for
parasite clearance time could be a pragmatic tool for studies with binary outcomes and once-daily sampling, both
for research and monitoring purposes.
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Background
Delayed Plasmodium falciparum response to artemisi-
nin is reported in Southeast Asia, and may spread to
other, more intensely malaria-endemic areas. Artemisi-
nin compounds contribute rapid parasite killing and
faster clearance to artemisinin-containing combination
therapy (ACT). Artemisinin tolerance/resistance manifests
itself with slower parasite clearance, while ACT remain
generally effective both clinically and parasitologically
[1-4]. Genomic studies are underway, which have gener-
ated so far two sets of putative markers of artemisinin
resistance - K13-propeller polymorphism [5], and a SNP
in the gene encoding a DNA repair protein RAD5 on
chromosome 13 (and possibly also on chromosome 10)
[6]. An in vitro assay (Ring Stage Assay) has also focused
on the very early phases of the ring-stage parasite [7].
However, as of today, in the clinic as well as in the field
the parasite clearance time (PCT) and its related clinical
phenotype (delayed PCT) remain the best practical surro-
gates of artemisinin in vivo resistance [8]; the problem is
that the frequent sampling (every six or eight hours)
required to measure PCT accurately and to estimate the
parasite clearance half-life [9] is practically difficult even
in research settings. Easier methods are needed for both
research and routine purposes. For example, failure to
clear by Day 3 (72 hours post-treatment start) is proposed
as a simple and accurate predictor of treatment failure
[10], requiring a single time-point and thus limiting the
workload in resource-limited settings.
Applying these and other measures both retrospect-
ively and prospectively to commonly-used ACT will help
understand trends and detect changes early enough to
prompt effective responses to contain the spread of re-
sistance. Artesunate-amodiaquine (ASAQ) is the second
most commonly used ACT in the world (the first-line
treatment in 22 out of 44 sub-Saharan African countries);
more than 200 million treatments of ASAQ Winthrop
have been distributed in Africa since the medication be-
came available in 2007 [11-13]. While ASAQ is generally
effective, the decreasing efficacy of AQ single-agent treat-
ment have been reported in some sub-Saharan African
settings [14,15]. Should artemisinin resistance occur there,
it is expected to result soon in treatment failures, particu-
larly in subjects with partial immunity, such as children in
high-transmission areas, or patients of all ages in low-
transmission areas. Monitoring ASAQ efficacy, particu-
larly in these groups, has therefore become all the more
important.
Greater understanding of factors influencing parasite
clearance is crucial, and requires the analysis of pooled
data from individual patient records. Therefore, this study
collected and analysed a large sample (over 15,000 pa-
tients) of individual patient data (of whom approximately
three-quarters were children under six years of age) from
clinical trials conducted in sub-Saharan Africa between
1999 and 2009.
Studies such as this will help provide the foundations
for further analyses of parasite clearance trends across
sub-Saharan malaria-endemic countries.
Methods
Study sites, design and patients
The database was constructed from studies identified
through a systematic review of clinical trials and per-
sonal contacts. To be included, efficacy or tolerability
monitoring studies had to have been conducted in sub-
Saharan Africa including any formulation of ASAQ to
any other single or combination treatment of uncompli-
cated falciparum malaria (non-severe or non hyperpara-
sitaemic) with follow-up of at least 28 days. For the
studies meeting these criteria, investigators were con-
tacted to provide individual patient data and the datasets
received were examined for inclusion [16].
Study endpoints
Out of the 27 studies included (conducted between 1999
and 2009), three were multi-country studies [17-19], two
studies compared ASAQ fixed and loose combination
[20-22] and three studies were non-comparative (in Sierra
Leone [23] and Senegal [24,25]). Details of the studies can
be found elsewhere [26-40]. There was one unpublished
study conducted in RDC (Cohuet, unpublished). The ana-
lysis of parasite clearance was by modified intent-to-treat
(ITT), including all participants who were randomized
and received the study medications. The primary endpoint
in all the studies included in the analysis was parasito-
logical efficacy, except one study about tolerability [22].
Follow-up ceased at the time of parasitological failure
(either primary or recurrence), loss to follow-up, proto-
col violation and no data were recorded thereafter.
Parasitaemia was recorded at enrolment (Day 0) and
post-treatment from Day 1 through Day 28, but sam-
pling schedules varied across studies during the first
seven days, with Day 1 or Day 2 not recorded in all. Con-
secutive parasite slide results (Day 0, Day 1, Day 2, Day 3,
Day 7) were available at 18 sites from five randomized
controlled trials (RCT) [17-19,26,27].
Definitions and analyses
Table 1 summarizes the measures and analyses con-
ducted. The risks of delayed parasite clearance by Day 2
and Day 3 and parasite clearance failure were analysed as
binary variables using age (continuous in years), baseline
parasitaemia (log transformed) as continuous variables,
anaemia (binary variable, haemoglobin < 10 g/dL), study
year (continuous) and study (categorical). The parasite
reduction ratio on Day (n) was defined as: parasitaemia
before treatment/parasitaemia on Day (n).
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The curve of the proportions of patients remaining
parasitaemic during follow-up was fitted using logistic
regression to give an estimate for clearance time. The fit-
ted model for the logit of the proportion of parasitaemic
patients over time and expressed in hours from the
logistic regression:
p dayð Þ ¼ Logit constant–a  day þ 1ð Þð Þ
with p 0ð Þ ¼ Logit constantð Þ
pPCT hourð Þ ¼ Logit −constant=að Þ–1ð Þ  24
In order to simplify the calculations of the predicted
parasite clearance time ((pPCT), for a patient or a group
of patients using the median time parasite clearance) the
patient population was classed into ten pre-treatment
parasite densities categories. A logistic model was fitted
for each group and the corresponding predicted PCT
was calculated, and once the results of predicted PCT
for the ten groups were obtained, a simple logarithmic
model was fitted with the aggregated results.
The risks, presented as adjusted risks ratios (AOR),
were assessed by logistic multivariate analysis with ran-
dom effect on the site in an attempt to account for po-
tential statistical heterogeneity while controlling for age
(continuous), parasitaemia before treatment (log-trans-
formed), anaemia (binary), and year (continuous). Cat-
egorical data were compared using the Chi-square or the
Fisher exact test as appropriate. The Spearman test was
used to analyse the relationship between clearance reduc-
tion and pre-treatment parasitaemia. Confidence intervals
(CI) were calculated at 95% and statistical significance was
set at p-value <0.05.
Table 1 Definitions
Measure Definition Population Analysis
Parasite clearance Patients’ conversion from a positive to a
negative parasite slide within 7 days
post-treatment start (independent of
whether it was sustained throughout
the entire duration of follow-up or there
was a recurrent episode).
All studies, whether comparative
or not (n = 15,017)
Observed median time of parasite
clearance
Delayed parasite clearance - Parasitaemia positive on Prevalence, risks by multivariate analysis
o Day 2
o Day 3
Parasite clearance failure - Day 2 parasitaemia > pre-treatment
parasitaemia
- Day 3 parasitaemia >25%
pre-treatment parasitaemia
- Consecutive positive slides up to Day 7
Parasite reduction ratio Relative difference (referent: parasite
before treatment)
ASAQ groups (n = 2,355) where
parasite densities were measured
once daily from Days 0 to 3 and
Day 7
Reduction rate
Predicted time of
parasite clearance
Modelling the time of parasite clearance Predict the time of parasite clearance
using the parasitaemia before treatment
and the proportions of positive patients
Figure 1 Flow chart, number of patients with parasitaemia results and daily results from Day 0 to Day 3 and Day 7.
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Table 2 Patients at enrolment
Year Site Total Under six years old Treatment Parasitaemia
n % ASAQ (n) Comparator (n) μL Anaemia (%)
2004 Angola-Caala 2004 137 137 100 69 68 29,180 28
2003 Angola-Kuito 2003 187 187 100 97 90 19,216 61
2008 Burkina faso - Nanoro 2008 810 810 100 295 515 20,831 83
2005 Burkina Faso Puytenga 2005 890 824 93 890 NA 15,210 76
2006 Cameroon 2006 166 79 48 110 56 24,627 8
2004 Congo-Kindamba 2004 298 298 100 101 197 25,890 64
2008 Gabon - 2008 226 226 100 80 146 22,265 69
1999 Gabon 1999 220 119 54 110 110 22,537 NA
2004 Guinee-Dabola 2004 220 220 100 110 110 37,493 73
1999 Kenya 1999 400 346 87 200 200 31,095 61
2009 Kenya 2009 54 0 0 54 NA 12,181 2
2009 Liberia 2009 1300 302 23 648 652 1,340 11
2006 Madagascar 2006 179 76 42 119 60 9,159 19
2004 Mali Bancouna 2004 753 714 95 252 501 15,468 44
2006 Mali Bougoula 2006 203 134 66 135 68 22,183 51
2008 Mozambique - Manhica 2008 420 420 100 210 210 39,023 62
2008 Nigeria - Afokang 2008 261 261 100 92 169 18,361 72
2008 Nigeria - Pamol 2008 233 233 100 82 151 18,177 73
2003 RDC Boende 2003 279 279 100 136 143 24,170 57
2002 Rwanda Mashesha 2002 122 122 100 61 61 14,729 45
2004 Rwanda Mashesha 2004 269 269 100 89 180 20,454 39
2002 Rwanda Rukara 2002 95 95 100 49 46 25,855 40
2004 Rwanda Rukara 2004 270 269 100 89 181 36,868 31
2002 Rwanda-Kicukiro 2002 91 91 100 48 43 13,457 31
2004 Rwanda-Kicukiro 2004 223 223 100 74 149 36,515 28
2000-5 Sen-Djembeye 2000-5 137 18 13 137 25,992 8
1999 Senegal 1999 321 123 38 160 161 40,386 NA
2006 Senegal 2006 392 11 3 264 128 7,991 47
2000-5 Sen-Mlomp 2000-5 723 74 10 723 NA 46,328 3
2000-5 Sen-Oussouye 2000-5 208 106 51 208 NA 19,142 NA
2004 Sierra Leone Kailahun 2004 126 126 100 126 NA 27,116 56
2003 South Sudan Nuba 2003 161 161 100 80 81 21,964 31
2003 Sudan Malakal 2003 269 269 100 134 135 22,881 86
2008 Uganda - Mbarara 2008 319 319 100 160 159 23,431 51
2003 Uganda Amudat 2003 212 212 100 106 106 18,410 49
2004 Uganda Tororo 2004 541 508 94 194 347 18502 71%
2005 Uganda Tororo 2005 408 388 95 204 204 21,480 40
2004 Uganda-Apac-2004 542 516 95 174 368 11,701 64
2004 Uganda-Arua-2004 534 509 95 174 360 23,927 63
2003 Uganda-Jinja-2003 543 370 68 189 354 34,337 40
2006 Uganda-Kampala-2006 730 358 49 242 488 10,581 11
2008 Zambia - Ndola 2008 245 245 100 85 160 36,401 85
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Ethical issues
All studies had been approved by the relevant ethics and
institution review committees as reported in the individ-
ual papers.
ASAQ treatment regimens
The majority of the patients were treated with individu-
ally formulated AS and AQ. The target dose was AS
12 mg/kg over three days and AQ 30 mg/kg over three
days except in Uganda where AQ was given at 25 mg/kg
(Day 0: 10 mg/kg, Day 1: 10 mg/kg, Day 2: 5 mg/kg).
The loose combinations of ASAQ were dosed based on
body weight, while in four studies the fixed dose com-
bination (FDC) ASAQ was based on age and weight
range [19-22]. The FDC was also given either once or
twice a day [19].
ASAQ FDC (Coarsucam™ Winthrop® Sanofi Aventis);
AS 25 mg/AQ 67.5 mg one tab/day for three days in chil-
dren 5–8.9 kg; AS 50 mg/AQ 135 mg one tab/day for
three days in children 9–17.9 kg; AS 100 mg/AQ 270 mg
one tab/day for three days in children 18–35.9 kg.
Comparator treatment regimens
i. ACT: artemether-lumefantrine (AL)(20 mg
artemether/120 mg lumefantrine) given according to
weight as one (5–14 kg), two (15–24 kg), three
(25–34 kg), and four (≥35 kg) tablets given twice
daily co-administrated with fat for three days;
Coartem™, Novartis); dihydroartemisinin-
piperaquine (DP) was given once daily over three days,
at the standard dosage of 2.25 mg/kg and 18 mg/kg of
dihydroartemisinin-piperaquine, respectively, rounded
up to the nearest half tablet (two formulations were
used: 20 mg dihydroartemisinin + 160 mg piperaquine
and 40 mg dihydroartemisinin +20 mg piperaquine,
Eurartesim™, Sigma-Tau, and in Rwanda, Artekin™,
Holley); AS + sulphadoxine- pyrimethamine
(SP)(AS 4 mg/kg/day; SP 25 mg/kg of
sulphadoxine and 1.25 mg/kg of pyrimethamine
administered in a co-formulated tablet as a single
dose);
ii. Non-ACT: AQ + SP (AQ 10 mg/kg/day for three
days and SP 25 mg/kg of sulphadoxine and 1.25 mg/
kg of pyrimethamine administered in a co-
formulated tablet (SP) as a single dose); chloroquine
(CQ)(25 mg/kg over three days) and SP; AQ
monotherapy (10 mg/kg/day for three days); AS
monotherapy (AS 12 mg/kg over five days).
Results
Overall 15,017 patients treated for uncomplicated P. fal-
ciparum malaria at 44 sites in 20 sub-Saharan African
countries were included in the analysis (Figure 1). The
proportion of patients treated with ASAQ was 51%
(n = 7,660) vs 49% (n = 7,357) on comparator treatments;
31% (4,848/15,017) of the patients had complete parasit-
aemia data every 24 hours up to Day 3 and then Day 7
(2,355 in ASAQ and 3,493 in comparator groups). Over-
all, the proportion of children under six years of age was
77%, and the overall geometric mean parasitaemia pre-
treatment was 16,964/μL (Table 2).
Parasitaemia on Day 2 and Day 3
Delayed parasite clearance, defined as the proportion of
patients still parasitaemic on Day 2 or Day 3 (analysed
as a binary variable) under ASAQ treatment in compara-
tive and non-comparative trials was analysed in 44 sub-
Saharan African sites over the period 1999–2009.
The proportion of patients on ASAQ who were still
parasitaemic on Day 2 was 8.6% (603/7,020, 95% CI 7.9-
9.3%) and ranged from 1.0% in Burkina Faso-Nanoro
(2008) and Congo-Kindamba (2004) to 57.1% in DRC-
Boende in 2003 (Additional file 1: Table S1). Using multi-
variate logistic regression with random effect on site and
controlling for treatment, the risk factors for a patient to
remain positive on Day 2 were higher parasitaemia before
treatment (AOR 2.12, 95% CI 1.91-2.35, p = 0.001) and an-
aemia (AOR 1.22, 95% CI 1.07-1.38, p = 0.001); no signifi-
cant difference in the risk of being parasitaemic on Day 2
was detected in RCT comparing ASAQ to other ACT: AL
(p = 0.245), DP (p = 0.762), AS + SP (p = 0.291), whereas
patients treated with non-ACT were at higher risk: AQ+
SP (AOR 14.53, 95% CI 11.36-18.59, p = 0.001), CQ + SP
(AOR 20.10, 95% CI 15.07-26.82, p = 0.001), or AQ (AOR
21.63, 95% CI 12.73-36.75, p = 0.001).
The proportion of patients treated with ASAQ who
were still parasitaemic on Day 3 was 1.5% (116/7,550,
95% CI 1.2-1.8%, of whom 44 in RDC-Boende), ranging
from 0% in many various sites across sub-Saharan Africa
to 55.9% in DRC-Boende. Using multivariate logistic ana-
lysis with random effects on sites, younger patients (AOR
0.94, 95% CI 0.90-0.98, p = 0.005) and patients with higher
parasitaemia at enrolment (AOR 2.43, 95% CI 1.98-3.00,
Table 2 Patients at enrolment (Continued)
2002 Zanzibar Kivunge 2002 297 296 100 148 149 16,500 78
2002 Zanzibar Micheweni 2002 105 105 100 54 51 16,777 87
Total 15017 11550 77 7660 7357 16,964 50
Legend: NA, non-applicable.
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p = 0.001) were at higher risk of remaining parasitaemic
on Day 3. Compared to ASAQ, the risk of being parasitae-
mic on Day 3 was higher for patients treated with a non-
ACT: AQ+ SP (AOR 15.70, 95% CI 7.43-33.16, p = 0.001),
AQ (AOR 16.38, 95% CI 7.82-34.34, p = 0.001), CQ + SP
(AOR 72.56, 95% CI 33.70-156.23, p = 0.001), while no
significant difference was detected with other ACT (AL,
p = 0.993; DP, p = 0.525; AS + SP, p = 0.190) (Figure 2).
Parasite clearance failure
Overall, patients treated with an ACT were at lower risk
of parasite clearance failure by Day 7 (AOR 0.03, 95% CI
0.01-0.12, p = 0.001, stratified by site) compared to non-
ACT (Table 3). The proportion of patients treated with
ASAQ who had a parasite clearance failure was 0.2%
(15/7,550, 95% CI 0.1-0.3%), mostly from one site (RDC-
Boende). Using multivariate analysis with random effect
on site, higher parasitaemia at enrolment (AOR 2.31,
95% CI 1.60-3.35, p = 0.001) was the only risk detected
for parasite clearance failure.
Parasite reduction ratio
Overall, in studies treating with ASAQ and recording
daily parasitaemia (n = 2,355), the parasite reduction
ratio (parasitaemia before treatment/parasitaemia on day
(n)) was 93.9% by Day 1 and 99.9% by Day 2 (Table 4).
The parasite reduction ratio ranged on Day 1 from 77.1%
in Mozambique to 99.2% in Kenya with a significant
correlation between clearance reduction on Day 1 and pre-
treatment parasitaemia (r = 0.098, p = 0.001, Spearman test,
individual data).
Predicted time of parasite clearance
The number of patients included in RCT at 17 sites with
complete parasitaemia record (every 24 hours from Day
0 to Day 3 plus Day 7) was 4,848 of whom 2,355 were
treated with ASAQ and 2,493 with a comparator drug.
Using logistic regression, the predicted time of parasite
clearance was overall ≈ 31 hours for a median baseline
parasitaemia of 27,125/μL, ranging from ≈ 19 hours for
patients with parasitaemia before treatment <2,500/μL
to ≈ 37 hours for patients with parasitaemia >100,000/μL
(Table 5).
Using the predicted PCT from the ten categories of
levels of baseline parasitaemia, a logarithmic relationship
was detected between the observed median baseline para-
sitaemia and the corresponding predicted PCT (Figure 3A).
The fitted curve was a logarithmic relationship defined by:
pPCT ¼ 3:614ln p0ð Þ – 6:135; r2 ¼ 0:94
where: pPCT ¼ predicted parasite clearance
time expressed in hours; and p0 ¼ parasitaemia
at enrolment pre−treatmentð Þ
The lower and upper bounds of the interval were fitted
using sites where the overall proportion of parasitaemic pa-
tients were <10% on Day 2 for the lower bound and >10%
for the upper bound with a coefficient of determin-
ation (r2) of 0.88 for both adjustments (Figure 3B).
The 10% threshold was in keeping with WHO recom-
mendations [41].
Figure 2 Delayed parasitaemia (Day 3) forest plot, artesunate/
amodiaquine vs comparator treatments. AL: artemether-
lumefantrine; AOR: adjusted odds ratio using multivariate logistic
regression with random effects; AQ: amodiaquine; AS: artesunate;
CQ: chloroquine; DP: dihydroartemisinin-piperaquine; fdc: fixed dose
combination; na: not applicable; SP: sulphadoxine-pyrimethamine.
Table 3 Proportion of patients with a parasite clearance
failure by Day 7 and by treatment groups
Treatment Parasite
clearance
failure
(number)
Total
number of
patients
Parasite clearance failure
Proportion
%
95% CI
lower
bound
95% CI
upper
bound
ASAQ 15 7,660 0.2 0.1 0.3
AL 3 2,391 0.1 0.0 0.4
DP 1 1,132 0.1 0.0 0.5
AS + SP 26 1,005 2.6 1.7 3.8
AQ 23 621 3.7 3.7 7.4
AQ + SP 9 1,257 0.7 0.3 1.3
AS 0 252 0.0 0.0 1.5
CQ + SP 78 699 11.2 8.9 13.7
Total 153 15,017 1.0 0.9 1.2
Zwang et al. Malaria Journal 2014, 13:114 Page 6 of 11
http://www.malariajournal.com/content/13/1/114
Discussion
This individual patient data analysis of parasite clearance
was conducted on a large sample (n ~15,000) of uncom-
plicated malaria treatments (predominantly paediatric;
three-quarters less than six years old) from 44 sites and
20 sub-Saharan African countries with different levels of
endemicity, covering the decade 1999–2009.
This analysis shows that rapid Plasmodium falcip-
arum clearance continues to be achieved in sub-Saharan
African patients treated with ACT, and in particular
with ASAQ, although direct within-site comparisons are
not available; it has therefore benchmarking value as
reference for future studies. This study also presents a
prediction formula for PCT as a pragmatic tool adapted
for studies with binary data (not quantitating parasite
densities) and once-daily sampling, such as those that
would be done at the typical study site in peripheral set-
tings and in routine surveillance by control programmes.
This prediction could apply to groups of patients as well
as to the individual patient.
Table 4 Clearance reduction, artesunate/amodiaquine groups
Country site
Parasitaemia,
geometric mean
N Parasite reduction ratio (individual data)
d1/d0 d2/d0 d3/d0 d7/d0
Burkina faso - Nanoro 2008 21,185 295 97.8% 100.0% 100.0% 100.0%
Cameroon 2006 24,129 110 97.0% 100.0% 100.0% 100.0%
Gabon - Fougamou 2008 21,117 80 98.6% 100.0% 100.0% 100.0%
Gabon 1999 20,867 108 98.2% 100.0% 100.0% 100.0%
Kenya 1999 30,040 199 94.5% 99.9% 100.0% 100.0%
Kenya 2009 12,193 54 99.2% 100.0% 100.0% 100.0%
Madagascar 2006 9,648 119 98.9% 100.0% 100.0% 100.0%
Mali Bougoula 2006 23,744 135 93.8% 99.9% 100.0% 100.0%
Mozambique - Manhica 2008 35,924 210 77.1% 99.8% 100.0% 100.0%
Nigeria - Afokang 2008 20,326 92 96.3% 99.7% 100.0% 100.0%
Nigeria - Pamol 2008 17,329 82 97.9% 99.8% 100.0% 100.0%
Senegal 1999 41,753 160 89.5% 99.8% 100.0% 100.0%
Senegal 2006 20,201 264 91.4% 99.7% 100.0% 100.0%
Uganda - Mbarara 2008 27,262 160 98.4% 100.0% 100.0% 100.0%
Zambia - Ndola 2008 35,887 85 91.9% 100.0% 100.0% 100.0%
Zanzibar Kivunge 2002 20,625 148 95.7% 100.0% 100.0% 100.0%
Zanzibar Micheweni 2002 18,236 54 95.2% 99.7% 100.0% 100.0%
Total 23,596 2355 93.9% 99.9% 100.0% 100.0%
Table 5 Predicted parasite clearance time by groups of parasitaemia before treatment and intervals,
artesunate/amodiaquine treatment
Parasitaemia at
enrolment (μL)
N Median Observed pPCT
Day 0 Day 1 Day 2 Day 3 Day 7 hour Lower bound Upper bound
<2,500 110 2,030 100% 24% 2% 1% 0% 19.0 NA NA
2,500-5,000 227 3,680 100% 44% 7% 1% 0% 24.4 21.7 26.7
5,000-10,000 294 7,290 100% 58% 10% 1% 0% 28.2 23.8 32.5
10,000-20,000 361 14,261 100% 65% 6% 1% 0% 29.1 25.1 36.2
20,000-30,000 261 25,044 100% 68% 10% 0% 0% 30.8 25.7 35.8
30,000-50,000 362 39,250 100% 73% 9% 1% 0% 31.6 27.2 37.1
50,000-75,000 252 61,372 100% 75% 12% 2% 0% 32.9 26.8 37.5
75,000-100,000 159 86,925 100% 79% 13% 0% 0% 34.0 29.8 39.9
>100,000 329 144,357 100% 84% 18% 3% 1% 37.3 33.1 40.7
TOTAL 2,355 27,125 100% 67% 10% 1% 0% 30.8 25.8 41.8
Legend: pPCT, predicted parasite clearance time.
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These results confirm the correlation between pre-
treatment parasitaemia and PCT [10], and offer an easy
way to calculate the typical PCT (in hour) using parasit-
aemia before treatment (p0) with ASAQ or other equiva-
lent treatments (pPCT = 3.614*ln(p0) – 6.135, r2 = 0.94).
There was also a (weaker) correlation between parasit-
aemia before treatment and the parasite reduction ratio
(PRR) at 24 h.
Monitoring treatment response and detecting artemisi-
nin resistance as early as possible have become a major
issue in malaria control. The rate at which treatment
clears parasites within the first few days is at present the
most useful practical test for ACT, as early response to
treatment relies predominantly on the parasite response
to artemisinin, independent of whether parasites are later
cleared for good through the combination of the longer-
lived companion drug and the host’s immune response.
The present analysis focused on initial response to ACT
treatment, as a proxy for artemisinin resistance and fail-
ure, and aimed to identify variables that were independ-
ently associated with persistent parasitaemia on Days 2
and 3 in settings where artemisinin resistance has prob-
ably not yet emerged.
Within the period covered by these studies, there was
no indication of delayed response to ACT. ACT cleared
parasites rapidly leaving very few patients with a low
parasitaemia on Day 3 (first day after the completion of
the three-day ACT regimen). In particular, with ASAQ
the parasite reduction ratio was 93.9% by Day 1 and
99.9% by Day 2; only 1.5% of the patients were still
Figure 3 Fitted curve of parasite clearance and intervals, artesunate/amodiaquine treatment. A: pPCT, predicted parasite clearance time.
B: pPCT, predicted parasite clearance time.
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positive on Day 3 (against a proposed threshold of 3%
indicating delayed response [10]). These data confirm that
pre-treatment parasitaemia is a risk factor for failing to
clear parasites on Day 2 and 3. They also show a clear
contribution of artemisinins to the speed of action: ACT
performed significantly better than non-ACT (whether
combinations or single-agent treatments); no difference
was detected between ACT (whether the artemisinin de-
rivative was artesunate, artemether or dihydroartemisinin).
Anaemia was an additional risk factor for failing to
clear parasites by Day 2; younger patient’s age for Day 3.
The only exception was the study conducted in DRC-
Boende (Cohuet, unpublished) which had a high propor-
tion of parasite clearance failures with both ASAQ and
AL. These findings are difficult to explain and should be
taken with caution, but one cannot exclude that there
might also have been a focus of resistant Plasmodium fal-
ciparum in the DRC. No subsequent studies are available
to confirm or belie this original study. Understanding the
dynamics of parasite clearance could help detect early
signs of artemisinin resistance and distinguish biologically
meaningful changes in early parasite clearance over time
from changes that may be due to the role of effect modi-
fiers like higher pre-treatment parasitaemia, young age
and anaemia by applying multivariate analysis.
Consistently with previous results [10] and the first-
order process of parasite clearance, there was a logarith-
mic correlation between patients’ pre-treatment parasit-
aemia and their pPCT; while developed using ASAQ
data, it was applied satisfactorily to other ACT within
this database as well as other studies. For example, in a
study conducted in Mali [42] where parasitaemia was
tested with frequent screenings (every eight hours) in
patients treated for uncomplicated P. falciparum with
artesunate for seven days and where there was no evi-
dence of delayed parasitaemia, the median parasitaemia
at enrolment (P0) was 27,070 μL and the observed me-
dian time of parasite clearance was 32 hours. Applying
the suggested method using the logarithmic correlation
found in the present paper (pPCT = 3.614*ln(P0) – 6.135)
gave very similar results (30.8 hours with intervals of 26.8
to 37.3 hours).
This simple method was tested to predict a “typical”
PCT in situations when resistance has not emerged.
However, this estimation of the predicted time to para-
site clearance is not without its limitations. The calcula-
tions may lack precision with studies sampling once a
day and at variable intervals from treatment intake (as it
might be the case for most clinical trials, especially on
the first day). It has been suggested that parasite clear-
ance rate can only be accurately estimated if sampling is
at least every six hours [43]; it is thus possible that data
could have been “over-analysed” in generating predicted
time of parasite clearance in this case. Although parasite
clearance half-life is the research reference to define slow
parasite clearance, sampling patients four times or even
twice a day is not feasible in routine monitoring, and
might be cumbersome even in research settings. Detecting
the first signs of artemisinin resistance in uncomplicated
P. falciparum will likely require a combination of more so-
phisticated studies and routine monitoring. Between para-
site clearance estimators [9] and Day 3 persistency [10],
simple estimations of PCT based on daily sampling may
add elements to facilitate comparisons and detection of
trends. It would be useful to compare methods for valid-
ation, including databases with delayed responses.
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